

Daniel T O connor

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11896624/daniel-t-oconnor-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

197
papers

8,646
citations

50
h-index

83
g-index

200
ext. papers

9,372
ext. citations

6.9
avg, IF

5.48
L-index

#	Paper	IF	Citations
197	The chromogranin-secretogranin family. <i>New England Journal of Medicine</i> , 2003 , 348, 1134-49	59.2	680
196	Secretion of chromogranin A by peptide-producing endocrine neoplasms. <i>New England Journal of Medicine</i> , 1986 , 314, 1145-51	59.2	428
195	Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. <i>Journal of Clinical Investigation</i> , 2005 , 115, 1942-52	15.9	246
194	Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk. <i>JAMA Psychiatry</i> , 2014 , 71, 423-31	14.5	222
193	Chromogranin A: immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands. <i>Life Sciences</i> , 1983 , 33, 1657-63	6.8	201
192	Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. <i>New England Journal of Medicine</i> , 1984 , 311, 764-70	59.2	196
191	Whole-genome analysis of sporadic amyotrophic lateral sclerosis. <i>New England Journal of Medicine</i> , 2007 , 357, 775-88	59.2	194
190	Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. <i>Regulatory Peptides</i> , 1983 , 6, 263-80		176
189	Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. <i>Journal of Hypertension</i> , 2002 , 20, 1335-45	1.9	156
188	Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA. <i>Journal of Biological Chemistry</i> , 1997 , 272, 1976-82	5.4	139
187	Biomarkers of PTSD: neuropeptides and immune signaling. <i>Neuropharmacology</i> , 2012 , 62, 663-73	5.5	135
186	Genomic predictors of combat stress vulnerability and resilience in U.S. Marines: A genome-wide association study across multiple ancestries implicates PRTFDC1 as a potential PTSD gene. <i>Psychoneuroendocrinology</i> , 2015 , 51, 459-71	5	125
185	Dopamine beta-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. <i>Human Genetics</i> , 1998 , 102, 533-40	6.3	117
184	The crucial role of chromogranins in storage and exocytosis revealed using chromaffin cells from chromogranin A null mouse. <i>Journal of Neuroscience</i> , 2008 , 28, 3350-8	6.6	107
183	Chromogranin A in uremia: progressive retention of immunoreactive fragments. <i>Kidney International</i> , 1990 , 37, 955-64	9.9	103
182	Population-based sample reveals gene-gender interactions in blood pressure in White Americans. <i>Hypertension</i> , 2007 , 49, 96-106	8.5	100
181	iPSCORE: A Resource of 222 iPSC Lines Enabling Functional Characterization of Genetic Variation across a Variety of Cell Types. <i>Stem Cell Reports</i> , 2017 , 8, 1086-1100	8	93

180	Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. <i>Circulation</i> , 2007 , 115, 2271-81	16.7	91
179	Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. <i>American Journal of Human Genetics</i> , 2004 , 74, 197-207	11	91
178	The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 1525-34	4.3	87
177	Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. <i>Journal of Biological Chemistry</i> , 1999 , 274, 2920-8	5.4	83
176	The catecholamine release-inhibitory "catestatin" fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses. <i>Molecular Pharmacology</i> , 2004 , 66, 1180-91	4.3	81
175	Catestatin: a multifunctional peptide from chromogranin A. <i>Regulatory Peptides</i> , 2010 , 162, 33-43		80
174	C-reactive protein, an intermediate phenotype for inflammation: human twin studies reveal heritability, association with blood pressure and the metabolic syndrome, and the influence of common polymorphism at catecholaminergic/beta-adrenergic pathway loci. <i>Journal of Hypertension</i> , 2007 , 25, 329-43	1.9	75
173	Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: prediction of catecholamines and response to stress in twins. <i>Physiological Genomics</i> , 2004 , 19, 277-91	3.6	75
172	Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. <i>American Journal of Medicine</i> , 1990 , 88, 607-13	2.4	74
171	A novel pathway of insulin sensitivity in chromogranin A null mice: a crucial role for pancreastatin in glucose homeostasis. <i>Journal of Biological Chemistry</i> , 2009 , 284, 28498-509	5.4	73
170	Tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis: discovery of common human genetic variants governing transcription, autonomic activity, and blood pressure in vivo. <i>Circulation</i> , 2007 , 116, 993-1006	16.7	73
169	Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk. <i>Journal of Clinical Investigation</i> , 2007 , 117, 2658-71	15.9	72
168	Identification of a novel sorting determinant for the regulated pathway in the secretory protein chromogranin A. <i>Journal of Cell Science</i> , 2002 , 115, 4827-41	5.3	68
167	Heritability and genome-wide linkage in US and Australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure. <i>Circulation</i> , 2008 , 118, 247-57	16.7	67
166	Rho kinase polymorphism influences blood pressure and systemic vascular resistance in human twins: role of heredity. <i>Hypertension</i> , 2006 , 47, 937-47	8.5	66
165	Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 5414-25	5.6	66
164	Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. <i>Clinical and Experimental Hypertension</i> , 2010 , 32, 278-87	2.2	64
163	Role of H ⁺ -ATPase-mediated acidification in sorting and release of the regulated secretory protein chromogranin A: evidence for a vesiculogenic function. <i>Journal of Biological Chemistry</i> , 2005 , 280, 3885-97	5.4	64

162	Heart rate variability characteristics in a large group of active-duty marines and relationship to posttraumatic stress. <i>Psychosomatic Medicine</i> , 2014 , 76, 292-301	3.7	63
161	Polymorphisms and haplotypes of the regulator of G protein signaling-2 gene in normotensives and hypertensives. <i>Hypertension</i> , 2006 , 47, 415-20	8.5	62
160	Proteolytic cleavage of chromogranin A (CgA) by plasmin. Selective liberation of a specific bioactive CgA fragment that regulates catecholamine release. <i>Journal of Biological Chemistry</i> , 2001 , 276, 25022-9	5.4	61
159	Neuroendocrine nicotinic receptor activation increases susceptibility to bacterial infections by suppressing antimicrobial peptide production. <i>Cell Host and Microbe</i> , 2010 , 7, 277-289	23.4	58
158	Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin. <i>Journal of Biological Chemistry</i> , 2003 , 278, 32058-67	5.4	57
157	Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules. <i>Journal of Biological Chemistry</i> , 2000 , 275, 22905-15	5.4	57
156	Catecholamine storage vesicle protein expression in genetic hypertension. <i>Blood Pressure</i> , 1999 , 8, 285-95	5.7	57
155	Cathepsin L colocalizes with chromogranin a in chromaffin vesicles to generate active peptides. <i>Endocrinology</i> , 2009 , 150, 3547-57	4.8	55
154	Common genetic mechanisms of blood pressure elevation in two independent rodent models of human essential hypertension. <i>American Journal of Hypertension</i> , 2005 , 18, 633-52	2.3	54
153	Sp1 and CREB mediate gastrin-dependent regulation of chromogranin A promoter activity in gastric carcinoma cells. <i>Journal of Biological Chemistry</i> , 1998 , 273, 34000-7	5.4	54
152	Predictors of risk and resilience for posttraumatic stress disorder among ground combat Marines: methods of the Marine Resiliency Study. <i>Preventing Chronic Disease</i> , 2012 , 9, E97	3.7	53
151	Chromogranin A correlates with norepinephrine release rate. <i>Life Sciences</i> , 1992 , 51, 519-25	6.8	53
150	Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin a null mouse. <i>Endocrinology</i> , 2009 , 150, 5027-35	4.8	52
149	Chromogranin A polymorphisms are associated with hypertensive renal disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2008 , 19, 600-14	12.7	51
148	Genetic loci associated with heart rate variability and their effects on cardiac disease risk. <i>Nature Communications</i> , 2017 , 8, 15805	17.4	50
147	Butyrylcholinesterase: association with the metabolic syndrome and identification of 2 gene loci affecting activity. <i>Clinical Chemistry</i> , 2006 , 52, 1014-20	5.5	49
146	Secretory granule biogenesis in sympathoadrenal cells: identification of a granulogenic determinant in the secretory prohormone chromogranin A. <i>Journal of Biological Chemistry</i> , 2006 , 281, 38038-51	5.4	49
145	Modulatory mechanism of the endogenous peptide catestatin on neuronal nicotinic acetylcholine receptors and exocytosis. <i>Journal of Neuroscience</i> , 2002 , 22, 377-88	6.6	49

144	A dynamic pool of calcium in catecholamine storage vesicles. Exploration in living cells by a novel vesicle-targeted chromogranin A-aequorin chimeric photoprotein. <i>Journal of Biological Chemistry</i> , 2004 , 279, 51107-21	5.4	48
143	Stimulus-transcription coupling in pheochromocytoma cells. Promoter region-specific activation of chromogranin a biosynthesis. <i>Journal of Biological Chemistry</i> , 1996 , 271, 28382-90	5.4	47
142	Sympatho-adrenal secretion in humans: factors governing catecholamine and storage vesicle peptide co-release. <i>Autonomic and Autacoid Pharmacology</i> , 1994 , 14, 187-200		46
141	Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. <i>Gastroenterology</i> , 2010 , 139, 836-45, 845.e1	13.3	45
140	Catestatin (chromogranin A(352-372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling. <i>Journal of Biological Chemistry</i> , 2012 , 287, 23141-51	5.4	45
139	Hereditary determinants of human hypertension: strategies in the setting of genetic complexity. <i>Hypertension</i> , 2008 , 51, 1456-64	8.5	45
138	Plasma norepinephrine kinetics, dopamine-beta-hydroxylase, and chromogranin-A, in hypothyroid patients before and following replacement therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990 , 70, 277-81	5.6	44
137	Pancreastatin-dependent inflammatory signaling mediates obesity-induced insulin resistance. <i>Diabetes</i> , 2015 , 64, 104-16	0.9	43
136	Human dopamine beta-hydroxylase (DBH) regulatory polymorphism that influences enzymatic activity, autonomic function, and blood pressure. <i>Journal of Hypertension</i> , 2010 , 28, 76-86	1.9	43
135	Renal albumin excretion: twin studies identify influences of heredity, environment, and adrenergic pathway polymorphism. <i>Hypertension</i> , 2007 , 49, 1015-31	8.5	43
134	Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin. <i>Endocrinology</i> , 2008 , 149, 749-57	4.8	42
133	A proposed role for chromogranin A as a glucocorticoid-responsive autocrine inhibitor of proopiomelanocortin secretion. <i>Endocrinology</i> , 1991 , 128, 1345-51	4.8	41
132	Proteomics of dense core secretory vesicles reveal distinct protein categories for secretion of neuroeffectors for cell-cell communication. <i>Journal of Proteome Research</i> , 2010 , 9, 5002-24	5.6	40
131	Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364-384)). <i>Cell and Tissue Research</i> , 2010 , 342, 353-61	4.2	38
130	Naturally occurring human genetic variation in the 3' untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 1468-81	15.1	38
129	Interactive effects of common beta2-adrenoceptor haplotypes and age on susceptibility to hypertension and receptor function. <i>Hypertension</i> , 2005 , 46, 301-7	8.5	38
128	Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a beta-strand/loop/beta-strand structure secured by hydrophobic interactions and predictive of activity. <i>Regulatory Peptides</i> , 1998 , 77, 43-53		37
127	Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. <i>Journal of Hypertension</i> , 2007 , 25, 2082-92	1.9	37

126	Arterial compliance by cuff sphygmomanometer. Application to hypertension and early changes in subjects at genetic risk. <i>Hypertension</i> , 1996 , 28, 599-603	8.5	37
125	Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 139-53	6.1	36
124	MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertension. <i>Human Molecular Genetics</i> , 2013 , 22, 3624-40	5.6	35
123	Neuroendocrine transcriptome in genetic hypertension: multiple changes in diverse adrenal physiological systems. <i>Hypertension</i> , 2004 , 43, 1301-11	8.5	35
122	Norepinephrine clearance, chromogranin A and dopamine beta hydroxylase in renal failure. <i>Kidney International</i> , 1990 , 37, 1357-62	9.9	35
121	The amino terminal sequences of bovine and human chromogranin A and secretory protein I are identical. <i>Biochemical and Biophysical Research Communications</i> , 1985 , 127, 380-3	3.4	35
120	Autonomic and hemodynamic origins of pre-hypertension: central role of heredity. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 2206-16	15.1	34
119	Role of reactive oxygen species in hyperadrenergic hypertension: biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin a (Chga) gene. <i>Circulation: Cardiovascular Genetics</i> , 2010 , 3, 414-25		34
118	Pro-hormone secretogranin II regulates dense core secretory granule biogenesis in catecholaminergic cells. <i>Journal of Biological Chemistry</i> , 2010 , 285, 10030-10043	5.4	34
117	Chromogranin A: localization and stoichiometry in large dense core catecholamine storage vesicles from sympathetic nerve. <i>Brain Research</i> , 1991 , 567, 188-96	3.7	34
116	Chromogranin A as tumor marker in medullary thyroid carcinoma. <i>Thyroid</i> , 1992 , 2, 5-10	6.2	33
115	Chromogranin a and the autonomic system: decomposition of heart rate variability and rescue by its catestatin fragment. <i>Endocrinology</i> , 2010 , 151, 2760-8	4.8	31
114	Pancreastatin-like immunoreactivity in human carcinoid disease. <i>Regulatory Peptides</i> , 1991 , 33, 55-70		31
113	The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. <i>Journal of Hypertension</i> , 2006 , 24, 895-904	1.9	30
112	Vesicular monoamine transport inhibitors. Novel action at calcium channels to prevent catecholamine secretion. <i>Hypertension</i> , 1996 , 28, 414-20	8.5	30
111	Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 1704-11	9.4	29
110	Primary culture of bovine chromaffin cells. <i>Nature Protocols</i> , 2007 , 2, 1248-53	18.8	29
109	Catecholamine storage vesicles and the metabolic syndrome: The role of the chromogranin A fragment pancreastatin. <i>Diabetes, Obesity and Metabolism</i> , 2006 , 8, 621-33	6.7	29

108	Renal hemodynamic changes during long-term antihypertensive therapy. <i>Clinical Pharmacology and Therapeutics</i> , 1981 , 29, 310-7	6.1	29
107	Mass spectrometry-based neuropeptidomics of secretory vesicles from human adrenal medullary pheochromocytoma reveals novel peptide products of prohormone processing. <i>Journal of Proteome Research</i> , 2010 , 9, 5065-75	5.6	28
106	Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells. <i>Biochemistry</i> , 2003 , 42, 6938-46	3.2	28
105	Genetic implication of a novel thiamine transporter in human hypertension. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1542-55	15.1	27
104	Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe. <i>Psychoneuroendocrinology</i> , 2013 , 38, 2378-82	5	27
103	Human tyrosine hydroxylase natural genetic variation: delineation of functional transcriptional control motifs disrupted in the proximal promoter. <i>Circulation: Cardiovascular Genetics</i> , 2010 , 3, 187-98		27
102	Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. <i>Journal of Hypertension</i> , 2010 , 28, 817-25	1.9	27
101	Assessment of multiple displacement amplification for polymorphism discovery and haplotype determination at a highly polymorphic locus, MC1R. <i>Human Mutation</i> , 2005 , 26, 145-52	4.7	27
100	Nicotinic acetylcholine receptors in glucose homeostasis: the acute hyperglycemic and chronic insulin-sensitive effects of nicotine suggest dual opposing roles of the receptors in male mice. <i>Endocrinology</i> , 2014 , 155, 3793-805	4.8	26
99	Dispersion of chromogranin/secretogranin secretory protein family loci in mammalian genomes. <i>Genomics</i> , 1996 , 33, 135-9	4.3	26
98	Novel peptide isomer strategy for stable inhibition of catecholamine release: application to hypertension. <i>Hypertension</i> , 2012 , 60, 1552-9	8.5	25
97	Molecular basis of neuroendocrine cell type-specific expression of the chromogranin B gene: Crucial role of the transcription factors CREB, AP-2, Egr-1 and Sp1. <i>Journal of Neurochemistry</i> , 2006 , 99, 119-33	6	25
96	Chromogranin A regulates renal function by triggering Weibel-Palade body exocytosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 1623-32	12.7	24
95	An ancestral variant of Secretogranin II confers regulation by PHOX2 transcription factors and association with hypertension. <i>Human Molecular Genetics</i> , 2007 , 16, 1752-64	5.6	24
94	Neuropeptide Y(1) Receptor NPY1R discovery of naturally occurring human genetic variants governing gene expression in cells as well as pleiotropic effects on autonomic activity and blood pressure in vivo. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 944-54	15.1	23
93	Biogenesis of the secretory granule: chromogranin A coiled-coil structure results in unusual physical properties and suggests a mechanism for granule core condensation. <i>Biochemistry</i> , 2007 , 46, 10999-1012	3.2	23
92	Human response to alpha2-adrenergic agonist stimulation studied in an isolated vascular bed in vivo: Biphasic influence of dose, age, gender, and receptor genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 388-403	6.1	23
91	Genetic variation at the human alpha2B-adrenergic receptor locus: role in blood pressure variation and yohimbine response. <i>Hypertension</i> , 2005 , 45, 1207-13	8.5	23

90	Chromogranin B: isolation from pheochromocytoma, N-terminal sequence, tissue distribution and secretory vesicle processing. <i>Regulatory Peptides</i> , 1991 , 33, 223-35		23
89	Dopamine-beta-hydroxylase: structural comparisons of membrane-bound versus soluble forms from adrenal medulla and pheochromocytoma. <i>Journal of Neurochemistry</i> , 1985 , 44, 411-20	6	23
88	Genome-wide case/control studies in hypertension: only the tip of the iceberg. <i>Journal of Hypertension</i> , 2010 , 28, 1115-23	1.9	23
87	The catecholamine biosynthetic enzyme dopamine beta-hydroxylase (DBH): first genome-wide search positions trait-determining variants acting additively in the proximal promoter. <i>Human Molecular Genetics</i> , 2014 , 23, 6375-84	5.6	22
86	Autonomic function in hypertension; role of genetic variation at the catecholamine storage vesicle protein chromogranin B. <i>Circulation: Cardiovascular Genetics</i> , 2009 , 2, 46-56		22
85	A common genetic variant in the 3'RUTR of vacuolar H ⁺ -ATPase ATP6V0A1 creates a micro-RNA motif to alter chromogranin A processing and hypertension risk. <i>Circulation: Cardiovascular Genetics</i> , 2011 , 4, 381-9		22
84	How sensitive and specific is measurement of plasma chromogranin A for the diagnosis of neuroendocrine neoplasia?. <i>Annals of the New York Academy of Sciences</i> , 1987 , 493, 379-86	6.5	22
83	Preserved renal perfusion during treatment of essential hypertension with the beta blocker nadolol. <i>Journal of Clinical Pharmacology</i> , 1982 , 22, 187-95	2.9	22
82	Secretin activation of chromogranin A gene transcription. Identification of the signaling pathways in cis and in trans. <i>Journal of Biological Chemistry</i> , 2003 , 278, 19986-94	5.4	21
81	Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A. <i>Regulatory Peptides</i> , 2004 , 118, 75-87		21
80	Common functional genetic variants in catecholamine storage vesicle protein promoter motifs interact to trigger systemic hypertension. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1463-75	15.1	20
79	Neuropeptidomic components generated by proteomic functions in secretory vesicles for cell-cell communication. <i>AAPS Journal</i> , 2010 , 12, 635-45	3.7	20
78	Naturally occurring variations in the human cholinesterase genes: heritability and association with cardiovascular and metabolic traits. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011 , 338, 125-33	4.7	19
77	Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart. <i>Regulatory Peptides</i> , 2010 , 165, 63-70		19
76	Early phenotypic changes in hypertension: a role for the autonomic nervous system and heredity. <i>Hypertension</i> , 2006 , 47, 331-3	8.5	19
75	Hormone storage vesicle proteins. Transcriptional basis of the widespread neuroendocrine expression of chromogranin A, and evidence of its diverse biological actions, intracellular and extracellular. <i>Annals of the New York Academy of Sciences</i> , 1994 , 733, 36-45	6.5	19
74	Plasma chromogranin-A in primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989 , 69, 950-5	5.6	19
73	Early inflammatory and metabolic changes in association with AGTR1 polymorphisms in prehypertensive subjects. <i>American Journal of Hypertension</i> , 2011 , 24, 225-33	2.3	18

72	Studies of the dysglycemic peptide, pancreastatin, using a human forearm model. <i>Annals of the New York Academy of Sciences</i> , 2002 , 971, 528-9	6.5	18
71	Molecular cloning, structure, and expression of dopamine-beta-hydroxylase from bovine adrenal medulla. <i>Journal of Neurochemistry</i> , 1990 , 55, 97-105	6	18
70	Neuropeptide Y (NPY): genetic variation in the human promoter alters glucocorticoid signaling, yielding increased NPY secretion and stress responses. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1678-89	15.1	17
69	Phenylethanolamine N-methyltransferase gene polymorphisms and adverse outcomes in acute kidney injury. <i>Nephron Clinical Practice</i> , 2010 , 114, c253-9		17
68	Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion. <i>Physiological Genomics</i> , 2006 , 25, 470-9	3.6	17
67	Skin pretreatment and the use of transdermal clonidine. <i>American Journal of Medicine</i> , 1991 , 91, 42S-49S	2.4	17
66	Human dopamine beta-hydroxylase promoter variant alters transcription in chromaffin cells, enzyme secretion, and blood pressure. <i>American Journal of Hypertension</i> , 2011 , 24, 24-32	2.3	16
65	Genetic variation within adrenergic pathways determines in vivo effects of presynaptic stimulation in humans. <i>Circulation</i> , 2008 , 117, 517-25	16.7	16
64	Heredity of endothelin secretion: human twin studies reveal the influence of polymorphism at the chromogranin A locus, a novel determinant of endothelial function. <i>Circulation</i> , 2007 , 115, 2282-91	16.7	16
63	Hereditary intermediate phenotypes in African American hypertension. <i>Ethnicity and Health</i> , 1996 , 1, 117-28	2.2	16
62	CSF chromogranin A-like immunoreactivity in schizophrenia. Assessment of clinical and biochemical relationships. <i>Schizophrenia Research</i> , 1991 , 6, 31-9	3.6	16
61	The trans-Golgi proteins SCLIP and SCG10 interact with chromogranin A to regulate neuroendocrine secretion. <i>Biochemistry</i> , 2008 , 47, 7167-78	3.2	15
60	The angiotensin II receptor (Agtr1a): functional regulatory polymorphisms in a locus genetically linked to blood pressure variation in the mouse. <i>Physiological Genomics</i> , 2003 , 14, 83-93	3.6	15
59	Malignant and benign pheochromocytoma: chromaffin granule transmitters and the response to medical and surgical treatment. <i>Annals of the New York Academy of Sciences</i> , 2002 , 971, 530-2	6.5	15
58	Assignment of the chromogranin A (Chga) locus to homologous regions on mouse chromosome 12 and rat chromosome 6. <i>Genomics</i> , 1993 , 17, 252-5	4.3	15
57	Catecholamine storage vesicles: role of core protein genetic polymorphisms in hypertension. <i>Current Hypertension Reports</i> , 2011 , 13, 36-45	4.7	14
56	Adrenergic polymorphism and the human stress response. <i>Annals of the New York Academy of Sciences</i> , 2008 , 1148, 282-96	6.5	14
55	Global metabolic consequences of the chromogranin A-null model of hypertension: transcriptomic detection, pathway identification, and experimental verification. <i>Physiological Genomics</i> , 2010 , 40, 195-207	2.6	13

54	Human tyrosine hydroxylase natural allelic variation: influence on autonomic function and hypertension. <i>Cellular and Molecular Neurobiology</i> , 2010 , 30, 1391-4	4.6	13
53	Reprint of: Catestatin: a multifunctional peptide from chromogranin A. <i>Regulatory Peptides</i> , 2010 , 165, 52-62		13
52	Neuroendocrine-specific and gastrin-dependent expression of a chromogranin A-luciferase fusion gene in transgenic mice. <i>Gastroenterology</i> , 2001 , 121, 43-55	13.3	13
51	Reduced renovascular resistance by clonidine. <i>Clinical Pharmacology and Therapeutics</i> , 1979 , 26, 572-7	6.1	13
50	Recirculation: a uremic syndrome complicating the use of prosthetic arteriovenous fistulas for hemodialysis. <i>Journal of Dialysis</i> , 1978 , 2, 251-9		13
49	Discovery of a novel target for the dysglycemic chromogranin A fragment pancreastatin: interaction with the chaperone GRP78 to influence metabolism. <i>PLoS ONE</i> , 2014 , 9, e84132	3.7	13
48	Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis. <i>American Journal of Nephrology</i> , 2010 , 32, 23-30	4.6	12
47	Isoprostane, an "intermediate phenotype" for oxidative stress heritability, risk trait associations, and the influence of chromogranin B polymorphism. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1338-50	15.1	12
46	Long human CHGA flanking chromosome 14 sequence required for optimal BAC transgenic "rescue" of disease phenotypes in the mouse Chga knockout. <i>Physiological Genomics</i> , 2010 , 41, 91-101	3.6	12
45	Neuroendocrine cell type-specific and inducible expression of chromogranin/secretogranin genes: crucial promoter motifs. <i>Annals of the New York Academy of Sciences</i> , 2002 , 971, 27-38	6.5	12
44	Development of a pharmacophore model for the catecholamine release-inhibitory peptide catestatin: virtual screening and functional testing identify novel small molecule therapeutics of hypertension. <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 5855-69	3.4	11
43	Chromogranin B: intra- and extra-cellular mechanisms to regulate catecholamine storage and release, in catecholaminergic cells and organisms. <i>Journal of Neurochemistry</i> , 2014 , 129, 48-59	6	11
42	A novel, catecholamine release-inhibitory peptide from chromogranin A: autocrine control of nicotinic cholinergic-stimulated exocytosis. <i>Advances in Pharmacology</i> , 1998 , 42, 260-4	5.7	11
41	Granulogenesis in non-neuroendocrine COS-7 cells induced by EGFP-tagged chromogranin A gene transfection: identical and distinct distribution of CgA and EGFP. <i>Journal of Histochemistry and Cytochemistry</i> , 2007 , 55, 487-93	3.4	11
40	Genome-wide linkage analysis of chromogranin B expression in the CEPH pedigrees: implications for exocytotic sympathochromaffin secretion in humans. <i>Physiological Genomics</i> , 2004 , 18, 119-27	3.6	11
39	The catecholamine release-inhibitory "catestatin" region of chromogranin a: early decline in humans at genetic risk of hypertension. <i>Annals of the New York Academy of Sciences</i> , 2002 , 971, 533-5	6.5	11
38	Identification of novel loci affecting circulating chromogranins and related peptides. <i>Human Molecular Genetics</i> , 2017 , 26, 233-242	5.6	11
37	Polymorphisms at the F12 and KLKB1 loci have significant trait association with activation of the renin-angiotensin system. <i>BMC Medical Genetics</i> , 2016 , 17, 21	2.1	10

36	Dopamine D1 receptor (DRD1) genetic polymorphism: pleiotropic effects on heritable renal traits. <i>Kidney International</i> , 2009 , 76, 1070-80	9.9	10
35	Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 3677-86	4.3	10
34	Genes and environment: novel, functional polymorphism in the human cathepsin L (CTSL1) promoter disrupts a xenobiotic response element (XRE) to alter transcription and blood pressure. <i>Journal of Hypertension</i> , 2012 , 30, 1961-9	1.9	10
33	Factitious pheochromocytoma: novel mimicry by Valsalva maneuver and clues to diagnosis. <i>American Journal of Hypertension</i> , 1995 , 8, 651-5	2.3	10
32	Clinical improvement in parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin A or basic fibroblast growth factor in ventricular fluid. <i>Experimental Neurology</i> , 1991 , 111, 276-81	5.7	10
31	Molecular Mechanism for Hypertensive Renal Disease: Differential Regulation of Chromogranin A Expression at 3RUntranslated Region Polymorphism C+87T by MicroRNA-107. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 1816-25	12.7	9
30	Human heart rate: heritability of resting and stress values in twin pairs, and influence of genetic variation in the adrenergic pathway at a microribonucleic acid (microrna) motif in the 3RUTR of cytochrome b561 [corrected]. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 358-68	15.1	9
29	The protein architecture of human secretory vesicles reveals differential regulation of signaling molecule secretion by protein kinases. <i>PLoS ONE</i> , 2012 , 7, e41134	3.7	9
28	Heritable influence of DBH on adrenergic and renal function: twin and disease studies. <i>PLoS ONE</i> , 2013 , 8, e82956	3.7	9
27	Common charge-shift mutation Glu65Lys in K+ channel β subunit KCNMB1: pleiotropic consequences for glomerular filtration rate and progressive renal disease. <i>American Journal of Nephrology</i> , 2010 , 32, 414-24	4.6	8
26	Urocortin 2 lowers blood pressure and reduces plasma catecholamine levels in mice with hyperadrenergic activity. <i>Endocrinology</i> , 2010 , 151, 4820-9	4.8	8
25	Systematic polymorphism discovery after genome-wide identification of potential susceptibility loci in a hereditary rodent model of human hypertension. <i>Blood Pressure</i> , 2011 , 20, 222-31	1.7	8
24	Natural variation within the neuronal nicotinic acetylcholine receptor cluster on human chromosome 15q24: influence on heritable autonomic traits in twin pairs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009 , 331, 419-28	4.7	8
23	Heredity and cardiometabolic risk: naturally occurring polymorphisms in the human neuropeptide Y(2) receptor promoter disrupt multiple transcriptional response motifs. <i>Journal of Hypertension</i> , 2013 , 31, 123-33	1.9	7
22	Contemporary approaches to genetic influences on hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2011 , 20, 23-30	3.5	7
21	Naturally occurring genetic variants in human chromogranin A (CHGA) associated with hypertension as well as hypertensive renal disease. <i>Cellular and Molecular Neurobiology</i> , 2010 , 30, 1395-400	4.6	7
20	Intracellular protein trafficking into catecholamine storage vesicles: novel chimeric photoproteins visualized by deconvolution fluorescence microscopy. <i>Annals of the New York Academy of Sciences</i> , 2002 , 971, 262-5	6.5	7
19	Chromaffin cell catecholamine secretion: bisindolylmaleimide compounds exhibit novel and potent antagonist effects at the nicotinic cholinergic receptor in pheochromocytoma cells. <i>Molecular Pharmacology</i> , 2002 , 61, 1340-7	4.3	7

18	CSF chromogranin A-like immunoreactivity in schizophrenia: relationships with REM latency and slow wave sleep. <i>Psychiatry Research</i> , 1992 , 42, 53-63	9.9	7
17	Granins and catecholamines: functional interaction in chromaffin cells and adipose tissue. <i>Advances in Pharmacology</i> , 2013 , 68, 93-113	5.7	6
16	Conserved regulatory motifs at phenylethanolamine N-methyltransferase (PNMT) are disrupted by common functional genetic variation: an integrated computational/experimental approach. <i>Mammalian Genome</i> , 2010 , 21, 195-204	3.2	6
15	Integrated computational and experimental analysis of the neuroendocrine transcriptome in genetic hypertension identifies novel control points for the cardiometabolic syndrome. <i>Circulation: Cardiovascular Genetics</i> , 2012 , 5, 430-40		5
14	Cox-2 promotes chromogranin A expression and bioactivity: evidence for a prostaglandin E2-dependent mechanism and the involvement of a proximal cyclic adenosine 5Rmonophosphate-responsive element. <i>Endocrinology</i> , 2007 , 148, 4310-7	4.8	5
13	Pharmacogenomics of hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2003 , 12, 61-70	3.5	5
12	Association of functional kallikrein-1 promoter polymorphisms and acute kidney injury: a case-control and longitudinal cohort study. <i>Nephron Clinical Practice</i> , 2012 , 122, 107-13		4
11	Catecholamine biosynthesis and secretion: physiological and pharmacological effects of secretin. <i>Cell and Tissue Research</i> , 2011 , 345, 87-102	4.2	4
10	Genetic variation within a metabolic motif in the chromogranin a promoter: pleiotropic influence on cardiometabolic risk traits in twins. <i>American Journal of Hypertension</i> , 2012 , 25, 29-40	2.3	4
9	A new common functional coding variant at the DDC gene change renal enzyme activity and modify renal dopamine function. <i>Scientific Reports</i> , 2019 , 9, 5055	4.9	3
8	Genetic variation at the delta-sarcoglycan (SGCD) locus elevates heritable sympathetic nerve activity in human twin pairs. <i>Journal of Neurochemistry</i> , 2013 , 127, 750-61	6	2
7	Chromogranin A pathway: from pathogenic molecule to renal disease. <i>Journal of Hypertension</i> , 2020 , 38, 456-466	1.9	2
6	Complex renal traits: role of adrenergic genetic polymorphism. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 1172-4	12.7	1
5	Proteomic analysis yields an unexpected trans-acting point in control of the human sympathochromaffin phenotype. <i>Circulation: Cardiovascular Genetics</i> , 2011 , 4, 437-45		1
4	Hypertension as a maladaptive "fight-or-flight" response?: confirmatory molecular genetic evidence from the human catecholamine biosynthetic pathway. <i>American Journal of Hypertension</i> , 2010 , 23, 1250-1	2.3	
3	Catecholamines, Pheochromocytoma, and Hypertension: Genomic Insights 2007 , 895-911		
2	Hereditary dysautonomias: current knowledge and collaborations for the future. <i>Clinical Autonomic Research</i> , 2003 , 13, 180-95	4.3	
1	Polymorphisms of α a and α b-adrenergic receptors help identify patients with arterial hypertension. <i>FASEB Journal</i> , 2007 , 21, A422	0.9	

